FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
Source: SeekingAlpha
2026-05-11 09:57:46 ET
Investment Overview - FDA Commissioner Marty Makary On The Brink
A couple of weeks ago, I covered the news that Replimmune ( REPL ), a Massachusetts-based biotech, had had its Biologics License Application ("BLA") requesting approval for its lead drug candidate RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma rejected for the second time....
Read the full article on Seeking Alpha
For further details see:
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-2.12% G/L:
$5.08 Last:
824,370 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
